CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
” Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 ” ”...
” Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company's lead SGT-003 program ” ...
Ballroom 3 at the Baltimore Convention Center was standing room only Tuesday afternoon at the annual meeting of the American Society of Gene & Cell Therapy. Several speakers took to the stage in succession to discuss ongoing efforts to improve adeno-associated virus purification and yield, aiming to improve both the safety and quality of these workhorse vectors of gene therapy.
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the Company), a life sciences company developing precision genetic medicines for neuromuscular and...
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
“ SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. “ “ Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 “ CHARLESTOWN, Mass.,...
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...